Allergy to soya products & peanut proteins. Discontinue use if persisting severe diarrhea, nausea & vomiting despite symptomatic treatment. Patients w/ inherited predisposition to bleeding or receiving full dose of anticoagulative treatment; higher CV risk including known CAD; thromboembolic events; previous abdominal surgery or recent history of hollow organ perforation; HTN, QT prolongation. Interrupt therapy if acute myocardial ischaemia signs or symptoms develop. Periodically measure systemic BP. Check hepatic transaminase & bilirubin levels before initiation of treatment, at regular intervals during 1st 3 mth & periodically thereafter or clinically indicated; reduce dose or interrupt therapy if transaminase (AST or ALT) elevations >3x ULN are measured. Permanently discontinue if any liver test elevations are associated w/ clinical signs or symptoms of liver injury eg, jaundice & GI perforation. Co-administration w/ pirfenidone. May impair wound healing. May affect ability to drive & use machines. Severe renal impairment (CrCl <30 mL/min). Not recommended in moderate (Child-Pugh B) & severe (Child-Pugh C) hepatic impairment. Reduced dose for mild hepatic (Child Pugh A) hepatic impairment. Renal impairment/failure, therapy adjustment should be considered. May promote the formation of aneurysms &/or artery dissections. Not to be used in patients w/ severe pulmonary HTN. Women of childbearing potential should use adequate contraception during & at least 3 mth after last dose. Discontinue during lactation. Childn.
Sign Out
